PharmaCyte Biotech Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Selling, General & Admin	5.11	4.91	3.94	6.11	5.99	3.7
Research & Development	0.36	0.39	0.44	0.41	0.47	0.69
Operating Expenses	5.46	5.3	4.38	6.52	6.46	4.39
Operating Income	-5.46	-5.3	-4.38	-6.52	-6.46	-4.39
Interest Expense	-	-	-	-	-	-0
Interest & Investment Income	1.3	1.11	1.42	3.4	1.94	0.16
Other Non Operating Income (Expenses)	-1.73	-7.74	9.11	5.45	0.2	-0
EBT Excluding Unusual Items	-5.89	-11.93	6.15	2.33	-4.32	-4.24
Gain (Loss) on Sale of Investments	-8.82	-6.06	26.53	-	-	-
Asset Writedown	-1.55	-1.55	-	-2	-	-
Legal Settlements	0.11	0.11	-2.02	-	-	-
Pretax Income	-16.15	-19.42	30.66	0.33	-4.32	-4.24
Net Income	-16.15	-19.42	30.66	0.33	-4.32	-4.24
Preferred Dividends & Other Adjustments	4.49	3.78	7.29	17.57	-	-
Net Income to Common	-20.63	-23.21	23.36	-17.24	-4.32	-4.24
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	9	8	7	10	19	16
Shares Outstanding (Diluted)	9	8	7	10	19	16
Shares Change	32.59%	14.31%	-23.50%	-50.84%	25.56%	971.73%
EPS (Basic)	-2.20	-2.77	3.19	-1.80	-0.22	-0.27
EPS (Diluted)	-2.20	-2.77	3.19	-1.80	-0.22	-0.27
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
EBIT	-5.46	-5.3	-4.38	-6.52	-6.46	-4.39

SEC Filings: 10-K · 10-Q